Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis
Authors
Keywords
-
Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-08-09
DOI
10.1111/jgh.14825
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn’s Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]
- (2019) Tadakazu Hisamatsu et al. Journal of Crohns & Colitis
- Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease
- (2018) Kenji Watanabe et al. Clinical Gastroenterology and Hepatology
- Combination Immunosuppression in IBD
- (2018) Steven Bots et al. INFLAMMATORY BOWEL DISEASES
- Evidence-based clinical practice guidelines for inflammatory bowel disease
- (2018) Katsuyoshi Matsuoka et al. JOURNAL OF GASTROENTEROLOGY
- Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
- (2018) Laura E. Targownik et al. Clinical Gastroenterology and Hepatology
- Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy
- (2018) Alessandro Sartini et al. DIGESTIVE DISEASES AND SCIENCES
- Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience
- (2018) Lieven Pouillon et al. INFLAMMATORY BOWEL DISEASES
- Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD
- (2017) Laura E. Targownik et al. INFLAMMATORY BOWEL DISEASES
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
- (2017) Marcus Harbord et al. Journal of Crohns & Colitis
- A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or Infliximab
- (2016) Kaoru Yokoyama et al. ADVANCES IN THERAPY
- Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
- (2016) J.-F. Colombel et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial
- (2016) Takayuki Matsumoto et al. Journal of Crohns & Colitis
- Effectiveness and Safety of Immunomodulators With Anti–Tumor Necrosis Factor Therapy in Crohn’s Disease
- (2015) Mark T. Osterman et al. Clinical Gastroenterology and Hepatology
- Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials
- (2015) Jennifer L. Jones et al. Clinical Gastroenterology and Hepatology
- Treatment of ulcerative colitis
- (2013) Wojciech Blonski et al. CURRENT OPINION IN GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Ulcerative colitis
- (2012) Ingrid Ordás et al. LANCET
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of ulcerative colitis and Crohn’s disease in Japan
- (2009) Keiko Asakura et al. JOURNAL OF GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started